Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults

Influenza Clinical Trial

Official title:

A Phase I/II Randomized Double Blind Controlled Study to Evaluate the Safety and Immunogenicity of GPO Seasonal Trivalent Inactivated Split Virion Influenza Vaccine in Healthy Thai Adults Aged Between 18 Years to 49 Years

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02894840
• Other study ID #: GPO Tri Fluvac Vaccine
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: November 2015
• Est. completion date: November 2016

Study information

• Verified date: March 2020
• Source: Mahidol University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The study is aim to evaluate the safety and immunogenicity of one dose (15 μg HA per strain per dose) of the GPO seasonal trivalent inactivated split virion influenza vaccine (Tri Fluvac) in healthy adults aged 18 to 49 years over 90 days post-injection.

Description:

This is a double blind randomized study consisting of two phases - Phase I and Phase II. The same vaccine, a seasonal trivalent inactivated split virion influenza vaccine [A/California/7/2009, reassortant virus NYMC X-181 (H1N1), A/Victoria/210/2009, reassortant virus NYMC X-187 (H3N2), and B/Brisbane/60/2008, reassortant virus NYMC BX-35 virus strains] will be given in both Phase I and Phase II of the study.

The vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm. After vaccination volunteers will remain at the clinic for at least 30 minutes to observe for any reactogenicity after immunization. Total follow-up is 90 days.

Blood specimens will be collected on Day 0 prior to vaccination, Day 21, Day 60, and day 90.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 340
• Est. completion date: November 2016
• Est. primary completion date: July 2016
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 49 Years

Eligibility

Inclusion Criteria:

• Healthy

• Age 18-49 years old

• Having Thai ID card or equivalent

• All hematology, biochemistry and urine analysis are within normal range or of no clinical significance (not higher than 1.5 time of normal value without any clinical finding from history and physical examination)

• Able to read and write and sign written informed consent form or assent form.

Exclusion Criteria:

• Known history of egg allergy

• Having had recently influenza infection confirmed as H1N1, H3N2, or Flu B within 3 months preceding enrolment to the trial

• Vaccination against influenza in the past 6 months preceding enrolment to the trial

• History of bronchial asthma, chronic lung diseases, chronic rhinitis

• History of immunodeficiency state

• History of immunosuppression < 6 months prior to immunization

• History of anaphylactic or other allergic reactions to influenza vaccine or any vaccine component or excipient (e.g. gentamicin or thimerosal)

• Acute infectious with fever > 38 degree Celsius and noninfectious diseases (within 72 hours) preceding enrollment in the trial

• The volunteers who have been taking immunoglobulin products or have had a blood transfusion during past 3 months before the beginning of the experiment

• Participation in other research study

• Pregnancy or plan to become pregnant for 60 days after enrollment or breast feeding

• Current alcohol abuse or drug addiction that might interfere with the ability to comply with trial procedures

• Any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled, or could interfere with the evaluation of the vaccine

Related Conditions & MeSH terms

• Influenza
• Influenza, Human

Intervention

Biological:
• an inactivated influenza vaccine
The vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.

Other:
• Placebo
The placebo will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.

Locations

Country	Name	City	State
n/a

Sponsors (3)

Lead Sponsor	Collaborator
Mahidol University	The Government Pharmaceutical Organization, World Health Organization

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Participants With Adverse Events	All Adverse Events during 90 days will be analysed in terms of percentage and relationship to study vaccine	90 days
Secondary	Number (Percentage) of Participants With Achieving Seroconversions or Significant Increase in Antihemagglutinin Antibody Titer.	Seroconversion is defined as a 4-fold rise in HAI titer in post-immunization serum relative to pre-immunization serum, or if pre-immunization serum had an undetectable titer (<1:10), attainment of a post-immunization titer of =1:40.	90 days
Secondary	Geometric Mean of Immune Response at Every Time of Assessment	The analysis was performed only as intention-to-treat (ITT). The antibody titer values were transformed into log10 titers for calculation of the GMT at every time of assessment (Days 0,21, 60 and 90)	90 days
Secondary	Geometric Mean of Immune Response Increase > 2.5 From Baseline of H1N1,H3N2 and B/Brisbane/60/2008 Antibody Titer	The analysis was performed only as intention-to-treat (ITT). The antibody titer values were transformed into log10 titers for calculation of the GMT at every time of assessment (Days 0, 21, 60 and 90). Proportion of increased in GMT Titer > 2.5 at each time of assessment compared with baseline (Day 0) was reported both phase I and phase II	90 days